Guizhou Xinbang Pharmaceutical Company Limited operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Guizhou Xinbang Pharmaceutical Company Limited with three other
companies in this sector in China:
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited
sales of 6.36 billion Chinese Renmimbi [US$900.25 million]
of which 66%
was Chinese Medicine),
Zhejiang Conba Pharmaceutical Co., Ltd.
(6.78 billion Chinese Renmimbi [US$960.62 million]
of which 98%
was Manufacturing), and
FUREN Group Pharmaceutical Co Ltd
(6.32 billion Chinese Renmimbi [US$894.41 million]
of which 80%
was Pharmaceutical Industry).
During the year ended December of 2018, sales at
Guizhou Xinbang Pharmaceutical Company Limited were 6.58 billion Chinese Renmimbi (US$931.64 million).
increase of 9.6%
versus 2017, when the company's sales were 6.00 billion Chinese Renmimbi.
This was the fifth consecutive year of sales increases at Guizhou Xinbang Pharmaceutical Company Limited
(and since 2013, sales have increased a total of 1,056%).
Sales of Medical Services saw an increase
16.3% in 2018, from
1.34 billion Chinese Renmimbi to 1.56 billion Chinese Renmimbi.
Not all segments of Guizhou Xinbang Pharmaceutical Company Limited experienced an increase in sales in 2018:
sales of Medicinal Manufacturing fell 10.7% to 775.07 million Chinese Renmimbi.